Monday June 21, 2:26 pm Eastern Time
Company Press Release
AURORA, ONTARIO--Interferon-a has been successfully delivered both dermally and transdermally, without the need for an injection, utilizing the Biphasix(tm) delivery system in a study of seventeen healthy human volunteers.
In a presentation to the Controlled Release Society in Boston, Professor Marianna Foldvari, of the College of Pharmacy and Nutrition at the University of Saskatchewan, presented the results of a study of the delivery of therapeutic proteins through human skin. The study showed a significant increase in anti-viral activity in the skin and in the blood following the application of an interferon-a-Biphasix(tm) patch when compared to a placebo.
"The results indicate significant levels of interferon-a in the skin and blood," said Dr. Foldvari. "This new delivery technology may also prove useful for the injectionless delivery of other protein therapeutics such as insulin. "
Interferons are prescription drugs presently given by injection to treat human papilloma virus ("HPV"), as well as other diseases including multiple sclerosis and hepatitis. Helix is developing an interferon-a Biphasix(tm) cream to combat HPV, a sexually transmitted disease linked to cervical cancer, that affects more than 24 million North Americans.
The Toronto Stock Exchange has not reviewed and does not acceptresponsibility
for the adequacy or accuracy of the content of this News Release. Information
contained in this news release includes forward- looking statements that
are subject to risks and uncertainties that could cause actual results
to differ materially. Helix BioPharma trades on the TSE under the symbol
Helix BioPharma Corp.
(905) 841-2300 ext. 232